Noradrenalin Altan (Noradrenaline Tartrate)

Noradrenaline tartrate, the active ingredient in Noradrenalin Altan, is a sympathomimetic presented as a solution for injection for intravenous use. It belongs to the vasopressor therapeutic class and is employed to raise blood pressure in patients with hypotension, septic shock or cardiac arrest, typically in intensive‑care or emergency environments.

GNH USA supplies Noradrenalin Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is manufactured under strict quality‑assurance protocols.

Noradrenalin Altan is a vasopressor used in critical‑care settings to counter severe hypotension.

- Hypotension: rapidly increases systemic vascular resistance and cardiac output to achieve target mean arterial pressure, supporting organ perfusion in acute low‑blood‑pressure states. - Septic shock: counteracts vasodilatory failure by stimulating alpha‑1 receptors, helping to restore hemodynamic stability in patients with severe infection‑related circulatory collapse. - Cardiac arrest: provides immediate vasoconstriction and inotropic support to maintain coronary and cerebral blood flow during advanced cardiac life support.

Noradrenalin Altan may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Tachycardia: increased heart rate. - Nausea: occasional gastrointestinal upset. - Anxiety or restlessness: nervousness during infusion.

Serious or Rare Side Effects: - Arrhythmias: potentially life‑threatening cardiac rhythm disturbances. - Myocardial ischemia: chest pain or infarction due to increased cardiac workload. - Severe hypertension: abrupt, excessive rise in blood pressure. - Tissue necrosis: extravasation injury at the injection site.

When using Noradrenalin Altan, clinicians should observe specific precautions to minimize risks. - Dose titration: adjust infusion rate to achieve target blood pressure while monitoring hemodynamics. - Cardiac monitoring: continuous ECG and arterial pressure monitoring are required. - Peripheral perfusion: assess limb circulation regularly to detect ischemia. - Concomitant vasopressors: avoid simultaneous use of other potent vasoconstrictors unless clinically justified. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Noradrenalin Altan can interact with several medications, influencing its efficacy or safety.

Major Interactions (Avoid): - Beta‑blockers: may blunt the inotropic response and precipitate severe hypotension. - MAO inhibitors: increase risk of hypertensive crisis when combined with sympathomimetics. - Tricyclic antidepressants: potentiate vasoconstrictive effects, raising hypertension risk.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: may enhance vasodilatory effects, requiring dose adjustments. - Diuretics: can exacerbate volume depletion, affecting blood pressure response. - Inhaled anesthetics: may cause additive cardiovascular depression.